Semaglutide, FITC labeled

Semaglutide, FITC labeled is a FITC (HY-66019) labeled Semaglutide (HY-114118), which is suitable for high-sensitivity fluorescence detection and imaging (Ex/Em = 488/525 nm) [1][2][3][4][5].

Product Specifications

Product Name Alternative

AHPN

UNSPSC

12171500

Target

Apoptosis; Autophagy; Bcl-2 Family; Fluorescent Dye; GLP Receptor; Insulin Receptor; p38 MAPK; α-synuclein

Type

Dye Reagents

Related Pathways

Apoptosis; Autophagy; GPCR/G Protein; MAPK/ERK Pathway; Neuronal Signaling; Others; Protein Tyrosine Kinase/RTK

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Cancer; Neurological Disease; Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/semaglutide-fitc-labeled.html

Purity

99.93

Solubility

DMSO : 6.67 mg/mL (ultrasonic)

Smiles

O=C([C@H](CC1=CN=CN1)NC(NC2=CC3=C(C4(C5=C(OC6=CC(O)=CC=C64)C=C(C=C5)O)OC3=O)C=C2)=S)NC(C)(C(N[C@H](C(NCC(N[C@H](C(N[C@@H](CC7=CC=CC=C7)C(N[C@H](C(N[C@H](C(N[C@@H](CC(O)=O)C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@@H](CC8=CC=C(C=C8)O)C(N[C@H](C(N[C@H](C(NCC(N[C@H](C(N[C@@H](C)C(N[C@@H](C)C(N[C@H](C(N[C@H](C(N[C@@H](CC9=CC=CC=C9)C(N[C@@H]([C@H](CC)C)C(N[C@@H](C)C(N[C@@H](CC%10=CNC%11=C%10C=CC=C%11)C(N[C@H](C(N[C@H](C(N[C@H](C(NCC(N[C@H](C(NCC(O)=O)=O)CCCNC(N)=N)=O)=O)CCCNC(N)=N)=O)C(C)C)=O)CC(C)C)=O)=O)=O)=O)=O)CCC(O)=O)=O)CCCCNC(COCCOCCNC(COCCOCCNC(CCC(NC(CCCCCCCCCCCCCCCCC(O)=O)=O)C(O)=O)=O)=O)=O)=O)=O)=O)CCC(N)=O)=O)=O)CCC(O)=O)=O)CC(C)C)=O)=O)CO)=O)CO)=O)C(C)C)=O)=O)CO)=O)[C@@H](C)O)=O)=O)[C@@H](C)O)=O)=O)CCC(O)=O)=O)C

Molecular Formula

C208H302N46O64S

Molecular Weight

4502.96

References & Citations

[1]Chang YF, et al. Semaglutide-mediated protection against Aβ correlated with enhancement of autophagy and inhibition of apotosis. J Clin Neurosci. 2020 Nov;81:234-239.|[2]Liu DX, et al. Semaglutide Protects against 6-OHDA Toxicity by Enhancing Autophagy and Inhibiting Oxidative Stress. Parkinsons Dis. 2022 Jul 13;2022:6813017.|[3]Wang C, et al. Semaglutide, a glucagon-like peptide-1 receptor agonist, inhibits oral squamous cell carcinoma growth through P38 MAPK signaling pathway. J Cancer Res Clin Oncol. 2025 Mar 7;151 (3) :103.|[4]Zhang L, et al. Semaglutide is Neuroprotective and Reduces α-Synuclein Levels in the Chronic MPTP Mouse Model of Parkinson's Disease. J Parkinsons Dis. 2019;9 (1) :157-171.|[5]Soto-Catalán M, et al. Semaglutide Improves Liver Steatosis and De Novo Lipogenesis Markers in Obese and Type-2-Diabetic Mice with Metabolic-Dysfunction-Associated Steatotic Liver Disease. Int J Mol Sci. 2024 Mar 4;25 (5) :2961.